Patients with mild to moderate Alzheimer’s disease (AD) who received supplementation with the omega-3 fatty acid docosahexaenoic acid, believed to possibly reduce the risk of AD, did not experience a reduction in the rate of cognitive and functional decline, compared to patients who received placebo, according to a new study.